患者与落败脐血单位共享HLA决定簇对双份脐血移植后复发的影响
该回顾性Eurocord研究纳入383例双份脐血移植(DUCBT),分析患者与落败脐血单位(PT-LU)间共享HLA错配对移植后复发的影响。结果发现PT-LU共享HLA-A错配及多个PT-LU共享HLA错配均与较低的7年复发率相关,多因素分析中多个PT-LU共享HLA错配仍与显著降低的7年移植后复发风险相关。
要点
- PT-LU共享HLA-A错配与较低7年复发率相关(16% vs 28%;P = .048)。
- 多个PT-LU共享HLA错配与较低复发风险相关(7% vs 29%;P = .003)。
- 多因素分析中多个PT-LU共享HLA错配仍与显著降低的7年复发风险相关。
核心结论
- 在DUCBT中,PT-LU共享HLA错配可激发胜出单位针对白血病的免疫反应,降低长期移植后复发风险,且DCBT在高危白血病患者中具有特定效用。
研究设计与样本
- 回顾性Eurocord研究,纳入383例双份脐血移植(DUCBT),聚焦移植后复发及PT-LU与胜出单位(WU)间的HLA错配。
主要发现
- PT-LU共享HLA-A错配与较低的7年复发发生率相关(16% vs 28%;P = .048)。
- 多个PT-LU共享HLA错配与较低的复发风险相关(7% vs 29%;P = .003)。
- 在患者与WU间≥2个HLA错配的DUCBT中,患者与WU间HLA错配数对复发发生率无显著影响,而多个PT-LU共享HLA错配仍与较低复发风险相关(7% vs 29%;P = .0038)。
- 在未发生2至4级急性移植物抗宿主病或慢性移植物抗宿主病的患者中,PT-LU共享HLA-A错配及多个PT-LU共享HLA错配均仍与显著较低的7年复发发生率相关。
- 多因素调整分析中,多个PT-LU共享HLA错配仍与显著降低的7年移植后复发风险相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During double umbilical cord blood transplant (DUCBT), the winning unit (WU) rejects the losing unit (LU) because of WU T cells directed against the LU mismatched HLA. This immune response might protect against relapse, especially when the patient and LU (PT-LU) share the same mismatch with the WU. To validate this hypothesis, a retrospective Eurocord study, conducted on 383 DUCBTs, focused on posttransplant relapse and HLA mismatches between PT-LU and the WU. A PT-LU HLA-A mismatch shared with the WU was associated with a lower 7-year relapse incidence (16% vs 28%; P = .048). In addition, multiple PT-LU shared HLA mismatches were also associated with a lower relapse risk (7% vs 29%; P = .003). In DUCBT with ≥2 HLA mismatches between patient and WU, the number of HLA mismatches between those did not significantly affect relapse incidence, whereas multiple PT-LU shared HLA mismatches remained associated with a lower relapse risk (7% vs 29%; P = .0038). Finally, considering patients who did not develop either grade 2 to 4 acute graft-versus-host disease or chronic graft-versus-host disease, a PT-LU shared HLA-A mismatch as well as multiple PT-LU HLA mismatches shared with the WU remained associated with a significantly lower 7-year relapse incidence. In multivariate adjusted analyses multiple PT-LU shared HLA mismatches remained associated with a significantly reduced 7-year posttransplant relapse risk. Our analysis indicates that, during DUCBT, PT-LU shared HLA mismatches prime an immune response of the WU against leukemia, reducing the long-term risk of posttransplant relapse, and that DCBT has particular utility in those with high-risk leukemia.
引用
- Wynn R, Volt F, Guardiola P, et al. Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation. Blood Adv. 2025. PMID: 40315369. doi:10.1182/bloodadvances.2025015938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。